TopBP1-IN-2
TopBP1-IN-2 is an inhibitor of the TopBP1 BRCT7/8 domain, with a pS1159 phosphopeptide competition IC50 of 6 nM. TopBP1-IN-2 also blocks the direct interaction between TopBP1-BRCT7/8 and the DNA-binding domain of mutp53R273H, exhibiting an IC50 of 25 nM. TopBP1-IN-2 selectively induces cancer cell apoptosis and inhibits their clonogenic formation, with no significant effects on normal cells. TopBP1-IN-2 is applicable in research related to breast cancer and ovarian cancer.
For research use only. We do not sell to patients.
- CAS No.: 902332-77-8
- Formula: C27H26N2O4
- Molecular Weight:442.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Topoisomerase Isoforms
More
Biological Activity
Description
In Vitro
TopBP1-IN-2 (compound 4B4) (5 μM; 20 h) selectively induces apoptosis in MDA-MB-468 and MDAH-2774 cancer cells, while no cytotoxic effect is observed in untransformed AML12 mouse hepatocytes[1].
TopBP1-IN-2 (0-2.5 μM; 24 h) inhibits the colony-forming ability of MDA-MB-468 breast cancer cells, with its IC50 falling in the range of 1 to 2.5 μM [1].
TopBP1-IN-2 (0.02-0.5 μM; 2 h) potently inhibits the binding of TopBP1-BRCT7/8 to its native pS1159 phosphopeptide substrate in a cell-free in vitro system, with an IC50 of 6 nM[1].
TopBP1-IN-2 (0.02-0.5 μM; 2 h) is a potent inhibitor of the TopBP1-BRCT7/8 and mutp53R273H protein-protein interaction, with an IC50 of 25 nM in cell-free biochemical assays[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-468, MDAH-2774, and AML12 mouse hepatocyte cells
-
Concentration:5 μM
-
Incubation Time:20 h
-
Result:Induced a pronounced apoptotic response and significantly elevated caspase-3/7 activity in MDA-MB-468 triple-negative breast cancer cells and MDAH-2774 ovarian cancer cells.
Showed no increase in caspase-3/7 activity in nontransformed AML12 mouse hepatocytes.
-
Cell Line:MDA-MB-468 breast cancer cells
-
Concentration:0.1, 1 and 2.5 μM
-
Incubation Time:24 h
-
Result:Inhibited the colony formation ability of MDA-MB-468 breast cancer cells with an IC50 between 1 and 2.5 μM.
Chemical Information
-
CAS No. 902332-77-8
-
Molecular Weight 442.51
-
Formula C27H26N2O4
-
SMILES
COC1=CC=CC=C1N(CC2)CCN2CC(C3=CC(O)=C(C4=CC=CC=C4)C=C3O5)=CC5=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)